Basic Information

Strain Name B6/JGpt-Krasem1Cin(loxP-stop-loxP-G12D)/Gpt
Strain Number T004551
Official Symbol Kras
Official Full Name Kirsten rat sarcoma viral oncogene homolog
Also Known As AI929937,KRas,KRas 2,Kras,Kiras,Kras2,Kras2,cKras,cKiras,p21B,ras
NCBI Number 16653
Research Areas Developmental Biology immune system , integument , cardiovascular system , Tumor research , nervous system , skeleton , vision/eye , hearing/ear , Muscle , respiratory system , Cell Proliferation , Cell death , reproductive system , digestive/alimentary system , Protein metabolism , liver/biliary system , renal/urinary system , endocrine/exocrine glands , homeostasis/metabolism , cell differentiation , Tumor model , craniofacial , embryo , growth/size/body , hematopoietic system , mortality/aging , pigmentation
Strain Background C57BL/6JGpt
Modification Type CRISPR/Cas9 Knockin(KI)
Genotyping Protocols
Related Links NCBI: 16653
Show More
View Quote Cart

Product Status

Inventory Status Live , Cryopreserved
Sale Status Available for Distribution
Health Status Specific pathogen free (SPF)

KRAS(KRAS Proto-Oncogene, GTPase) is a membrane-associated GTPase signaling protein that regulates proliferation, differentiation, and cell survival [1]. Missense mutations at codons 12, 13, and 61 lock the protein in its GTP-bound form thus permitting its constitutive interaction with andactivation of multiple effectors [2], which promoting effects on cell proliferation and cell survival. Mutations of KRAS are found in a variety of human malignancies, including in pancreatic cancer, colorectal cancer, and non-small cell lung cancer at high frequency. However, no direct RASinhibitors exist for cancer therapy. To study the relationship between the mutational activation of KRAS and tumorigenesis, we established B6-Loxp-Stop-Loxp Kras G12D (B6-KrasLSL-G12D) strain. Floxed Stop sequences will be deleted in the mouse genome when Cre recombinase exists, oncogenic KRAS G12Dproteinare expressed with endogenous levels following removal of the stop cassette, which allows tocontrol of the timing, location, and the multiplicity of tumor initiation. When B6-KrasLSL-G12Dmice crossed with B6-Lyz2 Cre mice(expressing Cre recombinase in myeloid cell lineage andlung), the offspring mice were developed lung tumor with inflammatory cell infiltration at 6weeks age. When B6-KrasLSL-G12D mice crossed with B6-Alb Cre mice (expressing Cre recombinase in liver and lung ), the offspring mice (at 36 weeks age) were developedhepatobiliary cancer and the whole liver was covered with tumor tissue. B6-KrasLSL-G12D mice model can be used to study the occurrence and development of cancer.


Strain Type

Load More

Research Area

Load More

Breeding Type

Sale Status